MIF and breast carcinoma: Finally, decreased expression levels of CCM1 and CCM3 proteins were observed under mPR-specific PRG actions among nPR(−) HBMVECs, HDMVECs, and RBMVECs as well as nPR(+) HUVECs, reinforcing that PRG works with its agonist, MIF, synergistically to inhibit the protein expression of CCM1/3 (Figure 1D), as seen previously in nPR(+/−) breast cancer cells [5,7,8,16].